Yellow means new targets from MabArray.

Multitude licensed out the exclusive global right(ex-China) to develop and commercialize AMT-754 to Adcendo.

Multitude licensed out the exclusive global right(ex-China) to develop and commercialize AMT-707 to OnCusp.

参考文献：

Wang et al., Sci. Adv. 2020. 6:eaax2271. An array of 60,000 antibodies for proteome-scale antibody generation and target discovery.

Weng et al., Cancer Discovery 2023. 13(4):950-973. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.

Shi et al., Cancer Res 2023;83:3783–95. A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma.

Weng et al., Mol Cancer Ther 2023;22:1013–27. AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors